Nicotinic acetylcholine receptors in glucose homeostasis: The acute hyperglycemic and chronic insulin-sensitive effects of nicotine suggest dual opposing roles of the receptors in male mice

Endocrinology (United States)

Volumn 155, Issue 10, 2014, Pages 3793-3805

  Vu, Christine U ^a   Siddiqui, Jawed A ^b   Wadensweiler, Paul ^a   Gayen, Jiaur R ^a,c   Avolio, Ennio ^b   Bandyopadhyay, Gautam K ^a,b   Biswas, Nilima ^b   Chi, Nai Wen ^a,b   O'Connor, Daniel T ^a   Mahata, Sushil K ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CATECHOLAMINE; CHLORISONDAMINE; CHLORMETHINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; MESSENGER RNA; NICOTINE; NICOTINIC RECEPTOR; NITRIC OXIDE; NORADRENALIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CATECHOLAMINE RELEASE; DIET RESTRICTION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLYCOGENOLYSIS; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIVER CELL CULTURE; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; NORADRENALIN BLOOD LEVEL; NUCLEOTIDE SEQUENCE; WEIGHT REDUCTION; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY; TIME;

ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; EPINEPHRINE; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; NICOTINE; NOREPINEPHRINE; RECEPTORS, NICOTINIC; TIME FACTORS;

EID: 84907223875     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1320     Document Type: Article

References (75)

1. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421:384-388.
2. Cheng PY, Lee YM, Law KK, Lin CW, Yen MH. The involvement of AMP-activated protein kinases in the anti-inflammatory effect of nicotine in vivo and in vitro. Biochem Pharmacol. 2007;74:1758-1765.
3. Bencherif M, Lippiello PM, Lucas R, Marrero MB. Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. Cell Mol Life Sci. 2011;68:931-949.
4. Vida G, Peña G, Deitch EA, Ulloa L. 7-cholinergic receptor mediates vagal induction of splenic norepinephrine. J Immunol. 2011; 186:4340-4346.
5. Baker RG, Hayden MS, Ghosh S. NF-B, inflammation, and metabolic disease. Cell Metab. 2011;13:11-22.
6. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415-445.
7. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-246.
8. Mabley JG, Pacher P, Southan GJ, Salzman AL, Szabó C. Nicotine reduces the incidence of type I diabetes in mice. J Pharmacol Exp Ther. 2002;300:876-881.
9. Liu RH, Kurose T, Matsukura S. Oral nicotine administration decreases tumor necrosis factor-alpha expression in fat tissues in obese rats. Metabolism. 2001;50:79-85.
10. Liu RH, Mizuta M, Matsukura S. Long-term oral nicotine administration reduces insulin resistance in obese rats. Eur J Pharmacol. 2003;458:227-234.
11. Wang X, Yang Z, Xue B, Shi H. Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance. Endocrinology. 2011;152:836-846.
12. Marrero MB, Lucas R, Salet C, et al. An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J Pharmacol Exp Ther. 2010; 332:173-180.
13. Martínez de Morentin PB, Whittle AJ, Fernø J, et al. Nicotine induces negative energy balance through hypothalamic AMP-activated protein kinase. Diabetes. 2012;61:807-817.
14. Seoane-Collazo P, Martínez de Morentin PB, Fernø J, Diéguez C, Nogueiras R, López M. Nicotine improves obesity and hepatic steatosis and ER stress in diet-induced obese male rats. Endocrinology. 2014;155:1679-1689.
15. Friedman TC, Sinha-Hikim I, Parveen M, et al. Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice. Endocrinology. 2012;153:5809-5820.
16. Sinha-Hikim I, Friedman TC, Shin CS, Lee D, Ivey R, Sinha-Hikim AP. Nicotine in combination with a high-fat diet causes intramyocellular mitochondrial abnormalities in male mice. Endocrinology. 2014;155:865-872.
17. Cena H, Fonte ML, Turconi G. Relationship between smoking and metabolic syndrome. Nutr Rev. 2011;69:745-753.
18. Miyatake N, Wada J, Kawasaki Y, Nishii K, Makino H, Numata T. Relationship between metabolic syndrome and cigarette smoking in the Japanese population. Intern Med. 2006;45:1039-1043.
19. Geslain-Biquez C, Vol S, Tichet J, Caradec A, D'Hour A, Balkau B. The metabolic syndrome in smokers. The D.E.S.I.R. study. Diabetes Metab. 2003;29:226-234.
20. Frati AC, Iniestra F, Ariza CR. Acute effect of cigarette smoking on glucose tolerance and other cardiovascular risk factors. Diabetes Care. 1996;19:112-118.
21. Rönnemaa T, Rönnemaa EM, Puukka P, Pyörälä K, Laakso M. Smoking is independently associated with high plasma insulin levels in nondiabetic men. Diabetes Care. 1996;19:1229-1232.
22. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM. Insulin resistance and cigarette smoking. Lancet. 1992;339:1128-1130.
23. Lakhan SE, Kirchgessner A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med. 2011;9:129.
24. Cui WY, Li MD. Nicotinic modulation of innate immune pathways via7 nicotinic acetylcholine receptor. J Neuroimmune Pharmacol. 2010;5:479-488.
25. Leite PE, Lagrota-Candido J, Moraes L, et al. Nicotinic acetylcholine receptor activation reduces skeletal muscle inflammation of mdx mice. J Neuroimmunol. 2010;227:44-51.
26. Scholze P, Orr-Urtreger A, Changeux JP, McIntosh JM, Huck S. Catecholamine outflow from mouse and rat brain slice preparations evoked by nicotinic acetylcholine receptor activation and electrical field stimulation. Br J Pharmacol. 2007;151:414-422.
27. Roe JH, Dailey RE. Determination of glycogen with the anthrone reagent. Anal Biochem. 1966;15:245-250.
28. Gayen JR, Saberi M, Schenk S, et al. A novel pathway of insulin sensitivity in chromogranin a null mice: A crucial role for pancreastatin in glucose homeostasis. J Biol Chem. 2009;284:28498-28509.
29. Varticovski L, Harrison-Findik D, Keeler ML, Susa M. Role of PI 3-kinase in mitogenesis. Biochim Biophys Acta. 1994;1226:1-11.
30. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased p85/ 55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes. 2005; 54:2351-2359.
31. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism. 1995;44:486-490.
32. O'Callaghan N, Dhillon V, Thomas P, Fenech M. A quantitative real-time PCR method for absolute telomere length. Biotechniques. 2008;44:807-809.
33. Clarke PB. Chronic central nicotinic blockade after a single administration of the bisquaternary ganglion-blocking drug chlorisondamine. Br J Pharmacol. 1984;83:527-535.
34. Strong SE, Caggiula AR, Saylor S, Ploskina TM. Time course of the selective peripheral antagonism of nicotine by chlorisondamine. Soc Neurosci Abstr. 1997;23:103.109.
35. Wenger BW, Bryant DL, Boyd RT, McKay DB. Evidence for spare nicotinic acetylcholine receptors and a beta 4 subunit in bovine adrenal chromaffin cells: Studies using bromoacetylcholine, epibatidine, cytisine and mAb35. J Pharmacol Exp Ther. 1997;281:905-913.
36. Sala F, Nistri A, Criado M. Nicotinic acetylcholine receptors of adrenal chromaffin cells. Acta Physiol. 2008;192:203-212.
37. Rogers SW, Mandelzys A, Deneris ES, Cooper E, Heinemann S. The expression of nicotinic acetylcholine receptors by PC12 cells treated with NGF. J Neurosci. 1992;12:4611-4623.
38. Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF, Boulter J. alpha10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci U S A. 2001;98:3501-3506.
39. Baizer L, Weiner N. Nerve growth factor treatment enhances nicotine-stimulated dopamine release and increases in cyclic adenosine 3:5-monophosphate levels in PC12 cell cultures. J Neurosci. 1985; 5:1176-1179.
40. Hodis J, Kutinová-Canova N, Potmesil P, et al. The role of adrenergic agonists on glycogenolysis in rat hepatocyte cultures and possible involvement of NO. Physiol Res. 2007;56:419-425.
41. Hutson NJ, Brumley FT, Assimacopoulos FD, Harper SC, Exton JH. Studies on the alpha-adrenergic activation of hepatic glucose output. I. Studies on the alpha-adrenergic activation of phosphorylase and gluconeogenesis and inactivation of glycogen synthase in isolated rat liver parenchymal cells. J Biol Chem. 1976;251:5200-5208.
42. Borgs M, Bollen M, Keppens S, Yap SH, Stalmans W, Vanstapel F. Modulation of basal hepatic glycogenolysis by nitric oxide. Hepatology. 1996;23:1564-1571.
43. Sugita H, Kaneki M, Tokunaga E, et al. Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am J Physiol Endocrinol Metab. 2002;282:E386-394.
44. de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol. 2007; 151:915-929.
45. Nakayama H, Numakawa T, Ikeuchi T. Nicotine-induced phosphorylation of Akt through epidermal growth factor receptor and Src in PC12h cells. J Neurochem. 2002;83:1372-1379.
46. Rothem DE, Rothem L, Soudry M, Dahan A, Eliakim R. Nicotine modulates bone metabolism-associated gene expression in osteoblast cells. J Bone Miner Metab. 2009;27:555-561.
47. Fang MA, Frost PJ, Iida-Klein A, Hahn TJ. Effects of nicotine on cellular function inUMR106-01 osteoblast-like cells. Bone. 1991; 12:283-286.
48. Marszalec W, Yeh JZ, Narahashi T. Desensitization of nicotine acetylcholine receptors: Modulation by kinase activation and phosphatase inhibition. Eur J Pharmacol. 2005;514:83-90.
49. Alzoubi KH, Aleisa AM, Alkadhi KA. Molecular studies on the protective effect of nicotine in adult-onset hypothyroidism-induced impairment of long-term potentiation. Hippocampus. 2006;16: 861-874.
50. Pogátsa G, Tamás J, Jr., Dubecz E. Effect of catecholamines on insulin secretion and liver glycogenolysis in the rat. Horm Metab Res. 1978;10:378-381.
51. Potter DE, Ellis S. Isoproterenol-and epinephrine-induced changes in blood glucose and tissue glycogen levels in normal and diabetic rats: The influence of alteration in endogenous insulin levels and state of nourishment. J Pharmacol Exp Ther. 1975;193:576-584.
52. Chu CA, Sindelar DK, Neal DW, Allen EJ, Donahue EP, Cherrington AD. Comparison of the direct and indirect effects of epinephrine on hepatic glucose production. J Clin Invest. 1997;99: 1044-1056.
53. Chu CA, Sindelar DK, Igawa K, et al. The direct effects of catecholamines on hepatic glucose production occur via alpha(1)-and beta(2)-receptors in the dog.AmJ Physiol Endocrinol Metab. 2000; 279:E463-473.
54. Garceau D, Yamaguchi N, Goyer R. Hepatic adrenoceptors involved in the glycogenolytic response to exogenous ()-norepinephrine in the dog liver in vivo. Life Sci. 1985;37:1963-1970.
55. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-789.
56. Gross DN, Wan M, Birnbaum MJ. The role of FOXO in the regulation of metabolism. Curr Diab Rep. 2009;9:208-214.
57. Lu M, Wan M, Leavens KF, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012; 18:388-395.
58. Horike N, Sakoda H, Kushiyama A, et al. AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinaseCgene expression in the liver. J Biol Chem. 2008;283:33902-33910.
59. An Z, Wang H, Song P, Zhang M, Geng X, Zou MH. Nicotineinduced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: A role for oxidant stress. J Biol Chem. 2007;282:26793-26801.
60. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell Signal. 2004;16:1211-1227.
61. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 1998;273:32377-32379.
62. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem. 2001;78:1219-1232.
63. Fiol CJ, Williams JS, Chou CH, Wang QM, Roach PJ, Andrisani OM. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression.Arole for glycogen synthase kinase-3 in the control of gene expression. J Biol Chem. 1994;269:32187-32193.
64. Zhou XY, Shibusawa N, Naik K, et al. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nat Med. 2004;10:633-637.
65. Jackson KJ, Walters CL, Damaj MI. Beta 2 subunit-containing nicotinic receptors mediate acute nicotine-induced activation of calcium/ calmodulin-dependent protein kinase II-dependent pathways in vivo. J Pharmacol Exp Ther. 2009;330:541-549.
66. Wu X, McMurray CT. Calmodulin kinase II attenuation of gene transcription by preventing cAMP response element-binding protein (CREB) dimerization and binding of the CREB-binding protein. J Biol Chem. 2001;276:1735-1741.
67. Xu TY, Guo LL, Wang P, et al. Chronic exposure to nicotine enhances insulin sensitivity through alpha7 nicotinic acetylcholine receptor-STAT3 pathway. PLoS One. 2012;7:e51217.
68. Inoue H, Ogawa W, Ozaki M, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med. 2004;10:168-174.
69. Inoue H, Ogawa W, Asakawa A, et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006;3:267-275.
70. Song DK, Im YB, Jung JS, et al. Central injection of nicotine increases hepatic and splenic interleukin 6 (IL-6) mRNA expression and plasma IL-6 levels in mice: Involvement of the peripheral sympathetic nervous system. FASEB J. 1999;13:1259-1267.
71. Moh A, Zhang W, Yu S, et al. STAT3 sensitizes insulin signaling by negatively regulating glycogen synthase kinase-3 beta. Diabetes. 2008;57:1227-1235.
72. Bugajski J, Hano J, Zdebska A. Effect of catecholamines and adrenergic antagonists on blood glucose, free fatty acids and liver glycogen levels in fed rats. Pol J Pharmacol Pharm. 1978;30:799-818.
73. Danulat E, Mommsen TP. Norepinephrine: A potent activator of glycogenolysis and gluconeogenesis in rockfish hepatocytes. Gen Comp Endocrinol. 1990;78:12-22.
74. Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol. 2009;169:236-248.
75. Mahata SK, Mahata M, Wakade AR, O'Connor DT. Primary structure and function of the catecholamine release inhibitory peptide catestatin (Chromogranin A344-364): Identification of amino acid residues crucial for activity. Mol Endocrinol. 2000;14:1525-1535.